Home
Issues
Aim & Scope
Open Access
Indexing
Why publish with us
Contact
Editorial Board
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
CrossMark
Data Policies
REVIEW
Severe Asthma: Definitions, risk factors and phenotype characterization
1
5th Pneumonology Department, Athens Chest Hospital “Sotiria”
Corresponding author
Penny Moraitaki
5th Pneumonology Clinic, Hospital for Diseases of the Chest “Sotiria” 152 Mesogion Av. Athens 115 27, Greece
5th Pneumonology Clinic, Hospital for Diseases of the Chest “Sotiria” 152 Mesogion Av. Athens 115 27, Greece
Pneumon 2010;23(3):276-292
KEYWORDS
ABSTRACT
The correct diagnosis of asthma is usually made easily and most patients with asthma respond to therapy. Approximately 5-10% of patients with asthma, however, have disease that is difficult to control despite administration of maximal doses of inhaled medications. It appears that asthma is a heterogeneous disorder which presents not as a single disease but rather as a complex of multiple, separate syndromes that overlap. Although the various different phenotypes of asthma have been long recognized, they are still poorly characterized. Improved phenotypical characterization and understanding of the underlying pathobiology are necessary for linkage of specific genotypes with clinical disease manifestations, for possible development of biomarkers and for devising advanced, phenotype-targeted asthma treatment. This review reports on the asthma phenotypes that have been best described and analyses the methods used to define them.
REFERENCES (115)
1.
Moore WC, Peters SP. Severe asthma: an overview. J Allergy Clin Immunol 2006; 117:487-94.
2.
Godard P, Chanez P, Siraudin L, Nicoloyiannis N, Duru G. Costs of asthma are correlated with severity. Eur Respir J 2002; 19:61- 7.
3.
Serra-Battles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12:1322-6.
4.
Bateman ED, Hurd SS, Barnes PJ, et al. Global Strategy For Asthma Management and Prevention: GINA Executive Summary. Eur Respir J 2008; 31:143-178.
5.
Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008; 32:545-554.
6.
Ogawa Y, Calhoun WJ. Phenotypic characterization of severe asthma. Curr Opin Pulm Med 2010; 16:48-54.
7.
Wenzel SE, Busse WW, for the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119:14-21.
8.
Moore WC, Bleecker ER, Curran-Everett D, et al, for the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119:405- 413.
9.
Miller MK, Johnson C, Miller DP, et al, for the TENOR study Group. Severity assessment in asthma: an evolving concept. J Allergy Clin Immunol 2005; 116:990-995.
10.
The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003; 22:470-477.
11.
Chanez P, Wenzel SE, Anderson GP, et al. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol 2007; 119:1337-1348.
12.
ten Brinke A., Sterk PJ, Masclee AAM, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005; 26:812-818.
13.
Gaga M, Papageorgiou N, Yiourgioti G, et al. Risk factors and characteristics associated with severe and difficult to treat asthma phenotype: an analysis of the ENFUMOSA group of patients based on the ECRHS questionnaire. Clin Exp Allergy 2005; 35:954-959.
14.
Miller MK, Lee JH, Blank PD, et al. TENOR risk score predicts healthcare in adults with severe or difficult to treat asthma. Eur Respir J 2006; 28:1145-1155.
15.
Gaga M, Zervas E, Chanez P. Update on severe asthma: what we know and what we need. Eur Respir Rev 2009; 18:58-65.
16.
Haselkorn T, Borish L, Miller DP, et al. High prevalence of skin test positivity in severe or difficult-to-treat asthma patients. J Asthma 2006; 43:745-752.
17.
Borish L, Chipps B, Deniz Y, et al. Total serum IgE leves in a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2005; 95:247-253.
18.
Chipps BE, Szefler SJ, Simons FE, et al. Demographic and clinical characteristics of children and adolescents with severe or difficult –to-treat asthma. J Allergy Clin Immunol 2007; 119:1156-1163.
19.
Green RH, Brightling CE, Bradding P. The reclassification of asthma based on subphenotypes. Curr Opin Allergy Clin Immunol 2007; 7:43-50.
21.
Bradding P, Green RH. Subclinical phenotypes of asthma. Curr Opin Pulm Med 2010; 10:54-59.
22.
Brasier AR, Victor S, Boetticher G, et al. Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. J Allergy Clin Immunol 2008; 121:30- 37.
23.
Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368:804-813.
24.
Dolan CM, Fraher KE, Bleecker ER, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004; 92(1):32-9.
25.
Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised control trial. Lancet 2002; 360:1715-21.
26.
Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006; 368:780-93.
27.
Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354:697-708.
28.
Minshall E, Chakir J, Laviolette M, et al. IL-1 expression is increased in severe asthma: association with epithelial cells and eosinophils. J Allergy Clin Immunol 2000; 105:232-238.
29.
Balzar S, Chu HW, Silkoff P, et al. Increased TGF-beta2 in severe asthma with eosinophilia. J Allergy Clin Immunol 2005; 115:110-117.
30.
Howarth PH, Babu KS, Arshad HS, et al. Tumor Necrosis Factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60:1012-18.
31.
Pepe C, Foley S, Shannon J, et al. Differences in airway remodelling between subjects with severe and moderate asthma. J Allergy Clin Immunol 2005; 116:544-549.
32.
Jatakanon A, Uasuf C, Maziak W, et al. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160:1532-39.
33.
Moore W, Everett D, Busse WW, et al. Validation of the ATS definition of severe asthma in the Severe Asthma Research Program. American Thoracic Society Annual Meeting, San Diego, CA, USA, 2006. A473.
34.
Wenzel SE, Everett D, Murphy J. Factors associated with severe and very severe asthma exacerbations. American Thoracic Society Annual Meeting, San Diego, CA, USA, 2005. A676.
35.
ten Brinke A, Ouwerkerk ME, Zwinderman AH, et al. Psychopathology in patients with severe asthma is associated with increased health care utilization. Am Respir Crit Care Med 2001; 163:1093-96.
36.
Kikuchi Y, Okabe S, Tamura G, et al. Chemosensitivity andperception of dyspnea in patients with a history of near-fatal asthma.New Engl J Med 1994; 330: 1329–34.
37.
Barreiro E, Gea J, Sanjuas C, Marcos R, Broquetas J, Milic-Emili J. Dyspnoea at rest and at the end of different exercises in patients with near-fatal asthma. Eur Respir J 2004; 24: 219–25.
38.
Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160: 1001–08.
39.
Covar RA, Spahn JD, Murphy JR, Szefler SJ. Progression of asthma measured by lung function in the childhood asthma management program. Am J Respir Crit Care Med 2004; 170: 234–41.
40.
Canonica GW. Treating asthma as an inflammatory disease. Chest 2006; 130(Suppl):21S-28S.
41.
Lee JY, Park SW, Chang HK, et al. A disintegrin and metalloproteinase 33 protein in patients with asthma: relevance to airflow limitation. Am J Respir Crit Care Med 2006; 173:729-735.
42.
Kotaru C, Schoonover KJ, Trudeau JB, et al. Regional fibroplast heterogeneity in the lung-implications for remodelling. Am J Respir Crit Care Med 2006; 173:1208-1215.
43.
Ten Brinke A, Zwinderman AH, Sterk PJ, et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164:744-748.
44.
Bumbacea D, Campbell D, Nguyen L, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 2004; 24:122-128.
45.
Fabri L.M, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2003;167:418-424.
46.
Welzer S. Physiologic and pathologic abnormalities in severe asthma. Clin Chest Med 2006; 27:29-40.
47.
Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2006; 117:522-543.
48.
Adcock IM, Barnes PJ. Histone deacetylation: an important mechanism in inflammatory lung diseases.COPD 2005; 2(4):445- 455.
49.
Adcock, IM, Ito K. Molecular mechanisms of corticosteroid actions. Monaldi Arch Chest Dis 2000; 55(3):256–266.
50.
Ito K, Yamamura S, e-Quaye SE, et al. Histone deacetylase 2– mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression. JEM 2006; 203:7–13.
51.
Ito K, Ito M, Elliott WM, Cosio B, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;352:1967–1976.
52.
Cosio BG, Tsaprouni L, Ito K, et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macro phages. J Exp Med 2004;200:689–695.
53.
Bacci E, Cianchetti S, Bartola ML, et al. Low sputum eosinophils predict the lack of responce to beclomethasone in symptomatic asthmatic patients. Chest 2006; 129:565-572.
54.
Cox G, Whitehead L, Dolovich M, Jordana M, Gauldie J, Newhouse MT. A randomised control trial on the effect of inhaled corticosteroids on airways inflammation in adult sigarette smokers. Chest 1999; 115:1271-77.
55.
Bhavsar P, Hew M, Khorasani N, et al. Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax 2008;63:784–790.
56.
Hew M, Bhavsar P, Torrego A, et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 2006;174:134-141.
57.
Adcock IM, Chung KF, Caramori G, et al. Kinase inhibitors and airway inflammation. Eur J Pharmacol 2006;533:118–132.
58.
Busse WW. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Med 2001;164:S12-17.
59.
Russo C, Polosa R. TNF-α as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clinical Science 2005; 109:135–142.
60.
Wenzel SE, Barnes PJ, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009 Apr 1;179(7):549-58.
61.
Moore W, Everett D, Busse WW et al. Identification of severe asthma subgroups based on age of onset. American Thoracic Society Annual Meeting, San Diego, CA, USA, 2006, A663.
62.
Miranda C, Busacker A, Balzar S, et al. Distinguising severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004; 113:101-108.
63.
Jenkins HA, Cherniack R, Szefler SJ, et al. A comparison of the clinical charateristics of children and adults with severe asthma. Chest 2003; 124:1318-1324.
64.
Burrows, B, Lebowitz, MD, Barbee, RA, et al. Findings before diagnosis of asthma among the elderly in a longitudinal study of a general population sample. J Allergy Clin Immunol 1991; 88:870-877.
65.
Tang EA, Wiesch DG, Samet JM. Epidemiology of asthma and allergic disease. In:Elliott Middleton J, ed. Allergy principles and practice. Philadelphia: Mosby 2003; 1127-68.
66.
Braun-Fahrlander C, Riedler J, Hertz U, et al. Enviromental exposure to endotoxin and ist relation to asthma in school-age children. N Engl J Med 2002; 347:869-77.
67.
Platts-Mills TA, Vaughan JW, Blumenthal K, Woodfolk JA, Sporik RB. Decreased prevalence of asthma among children with high exposure to cat allergen: relevance of the modified Th2 response. Mediators Inflamm 2001; 10(6):288–291.
68.
Plattts-Mills TA, Vaughan JW, Blumenthal K, Woodfolk JA, Sporik RB. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based crosssectional study. Lancet 2001; 357:752-756.
69.
Lau S, Illi S, Sommerfeld C, et al. The Multicentre Allergy Study Group. Early exposure to house-dust mite and cat allergens and development of childhood asthma: a cohort study. Lancet 2000; 356:1392–1397.
70.
Wahn U, Lau S, Bergmann R, et al. Indoor allergen exposure is a risk factor for sensitization during the first three years of life. J Allergy Clin Immunol 1997; 99:763-769.
71.
Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-E recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184- 90.
72.
Soler M, Matz J, Townley R, et al. The anti Ige-E antibody omalizumab reduses exacerbation and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-61.
73.
Mapp CE, Boschetto P, Maestelli P, Fabbri LM. Occupational asthma. Am J Respir Crit Care Med 2005; 172:280-305.
74.
Saetta M, Di Stefano A, Maestrelli P, et al. Airway mucosal inflammation in occupational asthma indused by toluene diisocyanate. Am Rev Respir Dis 1992; 145:160-68.
75.
Lemiere C, Malo JL, Boutet M. Reactive airway dysfunction syndrome due to chlorine: sequential bronchial biopsies and functional assessment. Eur Respir J 1997; 10:24144.
76.
Szczeklik A, Sanak M. The broken balance in aspirin hypersensitivity. Eur J Pharmacol 2006; 533:145-155.
77.
Szczeklik A. Stevenson DD. Aspirin-induced asthma: advances in pthogenesis,diagnosis and management. J Allergy Clin Immunol 2003; 111:913-21.
78.
Kim S, Park H. Pathogenesis of nonsteroidal anti-inflammatory rug-induced asthma. Curr Opin Allergy Clin Immunol 2006; 6:17-22.
79.
Murphy VE, Gibson PG. Premestrual asthma: prevalence,cycle to cycle variability and relationship to oral contraceptive use and menstrual symptoms. J Asthma 2008 Oct; 45(45):696-704.
80.
Sunday LN, Tran MM, Krause DN, Duckles SP. Estrogen and progestagens dfferentially modulate vascular proinflammatory factors. Am J Physiol Endocrinol Metab 2006. Published online Feb 21, 2006.
81.
Siroux V, Curt F, Oryszczyn MP, et al. Role of gender and hormone related events on Ige, atopy, and eosinophils in the Epidemiology study on the Genetics and Environment of Asthma, bronchial hyperresponsiveness and atopy. J Allergy Clin Immunol 2004 Sep; 114(3):491-8.
82.
Leckie MJ, Ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophiles, airway hyperresponsiveness and the response to allergen in patients with asthma. Lancet 2000; 356:2144–2148.
83.
Bryan SA, O'Connor BJ, Matti S, et al. Effects ofrecombinant human interleukin-12 on eosinophiles, airwayhyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2149–2153.
84.
Wenzel SE, Szefler SJ, Leung DYM, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma. Am J Respir Crit Care Med 1997; 156:737–743.
85.
Kay A. The Role of T Lymphocytes in Asthma. Allergy and Asthma in Modern Society: A Scientific Approach. Chem Immunol Allergy. Basel, Crameri R (ed): Karger, 2006, vol 91, pp 59-75.
86.
Louis R, Lau LC, Bron AO, et al. The relationship between airway inflammation and asthma severity. Am J Respir Crit Care Med 2000; 161:9-16.
87.
Berry MA, Shaw DE, Green RH, et al. The use of exhaled nitric oxide concentration to identify eosinophillic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy 2005; 35:1175-79.
88.
Silkoff PE, Lent AM, Busacker AA, et al. Exhaled nitric oxide identifies the persistent eosinophillic phenotype in severe refractory asthma. J Allergy Clin Immunol 2005; 116:1249-.
89.
Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352:2163-73.
90.
Malerba M, Ragnoli B, Radaeli A, Tantucci C. Usefulness of exhaled nitric oxide and sputum eosinophils in the long-term control of eosinophilic asthma. Chest 2008 Oct; 134(4):733- 739.
91.
Bernstein JA, Davis B, Alvarez-Puebla MJ, Nguyen D, Levin L, Olaguibel JM. Is exhaled nitric oxide a useful adjunctive test for assessing asthma? J Asthma 2009 Nov; 46(9):955-60.
92.
Berry M, Hargadon B, Morgan A, et al. Alveolar nitric oxide inadults with asthma: evidence of distal lung inflammation inrefractory asthma. Eur Respir J 2005; 25: 986–91.
93.
Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27:483-94.
94.
Barnes JP. Cytokine modulators as novel therapies for asthma. Annual Review of Pharmacology and Toxicology 2002; 42:81- 98.
95.
Haldar P, Brightling C, Hargadon B, et al. Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma. NEJM 2009; 360:973-984.
96.
Flood-Page P, Swenson C, Faiferman I, et al. A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma. Am J Respir Crit Care Med 2007; 176:1062- 1071.
97.
Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent astyhma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001; 119:1329-1336.
98.
James AL, Elliot JG, Abramson MJ, et al. Time to death, airway wall inflammation and remodelling in fatal asthma. Eur Respir J 2005; 26:429-34.
99.
Nguyen LT, Lim S, Oates T, et al. Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma. Respir Med 2005; 99:200-207.
100.
Hamilton LM, Torres-Lozano C, Puddicombe SM, et al. The role of the epidermal growth factor receptor in sustaining neutrophil inflammation in severe asthma. Clin Exp Allergy 2003; 33:233-240.
101.
Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of a subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57:875-79.
102.
Bacci E, Cianchetti S, Bartoli M, et al. Low Sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. Chest 2006; 129:565-72.
103.
Hoffjan S, Nicolae D, Ostrovnaya I, et al. Gene-environment interaction effects on the development of immune responses in the 1st year. Am J Hum Genet 2005; 76:696-704.
104.
Simpson A, Maniatis N, Jury F, et al. Polymorphisms in a disintegrin and metalloprotease 33 (ADAM##) predict impaired early-life lung function. Am J Respir Crit Care Med 2005; 172:55-60.
105.
Holgate ST, Yang Y, Haitchi HM, et al. The genetics of asthma: ADAM33 as an example of a susceptibility gene. Proc Am Thorac Soc 2006; 3:440-443.
106.
Sackesen C, Karaaslan C, Keskin O, et al. The effect of polymorphisms at the CD14 promoter and the TLR4 gene on asthma phenotypes in Turkish children with asthma. Allergy 2005; 60:1485-1492.
107.
Koppelman G. Gene by environment interaction in asthma. Curr Allergy Asthma Rep 2006; 6:103-11.
108.
Zhang J, Pare PD, Sandford AJ. Recent advances in asthma genetics. Respir Res 2008 Jan 15;9:4.
109.
Hall IP, Blakey JD, Al Balushi KA, et al. β2-Adrenoreceptor polymorhisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study. Lancet 2006; 368:771-779.
110.
Israel E, Chinchilli V, Ford J, et al. For the National Heart, Lung, and Blood Institute’s Asthma Clinical Research Network. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. The Lancet 2004; 364:1505–1512.
111.
Wardlaw AJ, Silverman M, Siva R, Pavord ID, Green R. Multidimensional phenotyping: towards a new taxonomy for airway disease. Clin Exp Allergy 2005; 35:1254–1262.
112.
Haldar P, Pavord ID, Shaw DE, et al. Cluster Analysis and Clinical Asthma Phenotypes. Am J Respir Crit Care Med 2008; 178:218- 24.
113.
Peters-Golden M, Swern A, Bird SS, Hustad CM, Grant E, Edelman JM. Influence of body mass index on the response to asthma controller agents. Eur Respir J 2006; 27:495–503.
114.
Christiani DC, Wang XR, Pan LD, et al. Longitudinal changes in pulmonary function and respiratory symptoms in cotton textile workers. A 15-yr follow-up study. Am J Respir Crit Care Med 2001; 163(4):847-53.
115.
Bakirci N, Kalaca S, Francis H, et al. Natural History and Risk Factors of Early Respiratory Responses to Exposure to Cotton Dust in Newly Exposed Workers. J Occ Environ Med 2007; 49:853-861.
Share
RELATED ARTICLE
| eISSN: | 1791-4914 |
| ISSN: | 1105-848X |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
